• Home
• About Us
  • Overview
  • Management
  • Board of Directors
  • Dynavax Europe
  • Careers
• Pipeline
  • Overview
  • Hepatitis B Vaccine
  • Hepatitis C
  • Hepatitis B
  • Asthma
  • Autoimmunity / Inflammation
  • Flu Vaccine
• Partners
• Technology
  • Immune System
  • ISS
  • IRS
  • Publications
• Investors
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Corporate Governance
  • Contact Us
• Contact Us

Investors

• Overview
• News & Events
• Stock Information
• Analyst Coverage
• Financials
• SEC Filings
• Corporate Governance
  • Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
• Contact Us

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.